TickerFacts.

X4 Pharmaceuticals, Inc (XFOR): Revenue

Annual figures by period end, from SEC filings.

$35.11M
Year ended 2025-12-31
$15.85M
Trailing 12 months to 2026-06-30
+63.6%
5-year compound annual growth
2018-12-31: $02019-12-31: $02020-12-31: $3.00M2021-12-31: $02022-12-31: $02023-12-31: $02024-12-31: $2.56M2025-12-31: $35.11M$35.11M
2018-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$35.11Mn/m2026-03-17, From 2025-01-01
2024-12-31$2.56Mn/a2026-03-17, From 2024-01-01
2023-12-31$0n/a2026-03-17, From 2023-01-01
2022-12-31$0n/a2025-03-26, From 2022-01-01
2021-12-31$0-100.0%2023-03-21, From 2021-01-01
2020-12-31$3.00Mn/a2023-03-21, From 2020-01-01
2019-12-31$0n/a2022-03-17, From 2019-01-01
2018-12-31$0n/a2021-03-19, From 2018-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$35.11Mn/m
C4 Therapeutics, Inc. (CCCC)2025-12-31$35.95M+1.0%
Precision Biosciences Inc (DTIL)2025-12-31$34.26M-50.1%
Kymera Therapeutics, Inc. (KYMR)2025-12-31$39.21M-16.7%
Sangamo Therapeutics, Inc (SGMOQ)2025-12-31$39.55M-31.6%
Voyager Therapeutics, Inc. (VYGR)2025-12-31$40.37M-49.5%
Editas Medicine, Inc. (EDIT)2025-12-31$40.52M+25.4%
Scilex Holding Co (SCLX)2025-12-31$30.25M-46.5%
Fennec Pharmaceuticals Inc. (FENC)2025-12-31$44.64M-6.1%

Compare XFOR, CCCC, DTIL, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗